Taiwan's case : American Ginseng (Radix Panacis Quinquefolii)

Hsi-Lin Chiu Ph.D. Nov 21, 2017

Medical and Pharmaceutical Industry Technology and Development Center



1



Outline

PDC-339 as an example
Control of Raw Material
Preparation of Substance and Product
Specification of PDC-339
Scope of PDC-339 products

PDC-339 as an example

formulation	SiJunZiTang (四君子湯 ; four mild drugs decoction)*			
classification	Ginseng Radix (人蔘)	Atractylodis Rhizoma (白朮)	Poria (茯苓)	Glycyrrhizae Radix (甘草)
君 (The active components)	Radix •			
臣 (Assist)				
佐 (Send)				
使 (Adjuvant drug)				
Functions	to benefit digestive system	to modulate the immune system	to eliminate the dampness	to adjust the functions of ingredients
*Prescription of Ancient Son Dynasty (宋朝太平惠民和劑局方)				
Strategy: from multiple herbs to single herb				
(Gins) 財團法人醫藥工業技術發 Medical and Pharmaceutic	eng Radix→A1 發展中心 cal Industry Technology and De	merican Ginseng) evelopment Center		3

PDC-339 as an example

Pre-clinical studies



Chemistry, Manufacturing and Control

(Quality)

財團法人醫藥工業技術發展中心 C Medical and Pharmaceutical Industry Technology and Development Center

American Ginseng-Description

- Fusiform, cylindrical or conical, 3-20 cm (occasionally up to 24 cm) long, 4-28 mm (occasionally up to 34 mm) in diameter.
- Externally yellowish-brown, yellowish-white, pale yellowish-brown or pale yellowish-white, exhibiting transverse annulations and linear lenticels, and showing shallow, fine and dense longitudinal wrinkles, and scars of rootlets.
- The middle and lower part of the main root, with one to several lateral roots, are mostly broken off. In some cases, the upper end presents remains of a rhizome (Lutou), with prominent annular nodes. Stem scars (Luwan) rounded or semirounded, with adventitious roots (Ding) remaining or already broken off.

Odour slight but characteristic; taste slightly bitter, gradually becoming sweet.



財團法人醫藥工業技術發展中心 C Medical and Pharmaceutical Industry Technology and Development Center

American Ginseng-Microscopic Identification

- Transverse section Cork consists of 6-8 rows of elongated tangential cells, with several layers often peeled off at the outer side.
- Resin canals scattered, surrounded by 5-11 secretory cells. In the phloem, resin canals are frequent and usually arranged in 1-3 concentric rings, the rays in the outer part with clefts.
- Vessels mainly reticulate and scalariform, but annular and spiral vessels can also be observed.
- Cortex consists of more than 10 rows of parenchyma cells, some containing cluster of calcium oxalate.
- Cambium ring distinct. Vessels scattered singly or in groups of 2-10, with interrupted radial arrangement, and lignified or slightly lignified. Rays consist of 1-4 rows of cells wide. Parenchyma cells contain starch granules.

Microscopic Identification

Transverse Section

Cambium



Scalariform Vessel



Reticulate Vessel

財團法人醫藥工業技術發展中心 C Medical and Pharmaceutical Industry Technology and Development Center \square

Microscopic Identification



Calcium Oxalate Clustered Crystal



Resin Canal



Specification of RM				
Test Item	Acceptance Criteria			
Botanical Characteristics	Transverse section shown light brown circular rings around cambium with scalarifrom, reticulated vessels ; reddish brown resin material around epidermis and core ; abundant of oxalic acid calcium crystals spread around epidermis and core. Possesses unique odor.			
Identifications	TLC Same <i>Rf</i> value as reference standards for A, B, C, D, E and F.			
Assay	HPLC, A quantity of A, C, D and E. A mg/g ; C NLT mg/g ; D NLT mg/g ; E NLT mg/g			
Loss on Drying	Not More Than 13.0%			
Total Ash	Not More Than 7.0%			
Acid Insoluble Ash	Not More Than 1.0%			
Water Extractives	Not Less Than 25.0%			
Alcohol Extractives	Not Less Than 24.0%			

財團法人醫藥工業技術發展中心

TD

TIC Medical and Pharmaceutical Industry Technology and Development Center

TLC&STD (Ginsenosides-saponin)





Medical and Pharmaceutical Industry Technology and Development Center

Preparation of Substance and Product



Raw Material Extraction (Temperature and time of extraction) Crude extracts (Solid content rate, Yield) **Steps** (Time, Solid content, TLC identification) **Dries** (In-process control) **Drug substance** (QC analysis) Mix drug substance with excipients **Granulation** (In-process control) Drug product (QC analysis)



Pharmacological Studies



14



Stability Study-Pharmacological (Biological)





•28-Day Subacute Oral Toxicity Study-Conclusion

The results of this 28-day oral toxicity study of PDC-339 in rats did not indicate any significant drug treatment related differences in mortality, clinical signs, body weights, total body weight gains, food consumption, ophthalmologic examination, urinalysis, hematology, serum chemistry, organ weights, organ to brain weight ratio, as well as the gross changes between the control, low, medium and high dose groups. In addition, there was no drug treatment related histopathological changes observed among the control and treatment animals in this study. Nasal hemorrhage and corresponding histopathological lesions in lung were observed in one control male rat, these findings were believed to be associated with dosing accident.

In conclusion, the results of this study suggest that PDC-339 did not induce any observable adverse effects in SD rats dosed orally with dose level up to 3000 mg/kg/day for 28 days. Therefore, the 28-day NOAEL for rats ingesting PDC-339 is determined to be greater than 3000 mg/kg/day.

The information generated from this subacute toxicity study can be used for extrapolating a safety margin dose for human consumption of PDC-339.

Scope of PDC-339 products



G Medical and Pharmaceutical Industry Technology and Development Center

THANK YOU FOR YOUR ATTENTION!!

